WEEDELICIOUS

In our first post, we gave a general overview of cannabis benefits and the potential of industrial hemp. Today we want to dig into something more specific: what the scientific literature actually says about using cannabis to treat certain conditions. This is delicate territory, often described either with too much enthusiasm or too much skepticism. Let’s try to bring some clarity by distinguishing between solid evidence, promising-but-preliminary results, and purely anecdotal observations.

Areas With the Most Established Evidence

Chronic pain, particularly neuropathic pain. This is probably the most studied area. Neuropathic pain is notoriously difficult to treat with conventional therapies, and several randomized clinical trials have shown significant symptom improvement in patients treated with cannabis-based preparations, with an overall acceptable tolerability profile when therapy is properly managed by a physician.

Spasticity in multiple sclerosis. Here too the evidence is relatively strong: oral preparations combining THC and CBD have shown lasting benefits over time, with a limited incidence of severe side effects. It’s no coincidence that several European countries have cannabinoid-based medications specifically approved for this indication.

Drug-resistant epilepsy. Cannabidiol (CBD) has arguably produced the most solid and “official” evidence of all in this field, to the point of leading to regulatory approval of CBD-based medications for certain severe forms of childhood epilepsy (such as Dravet syndrome and Lennox-Gastaut syndrome) — conditions that often don’t respond to traditional antiepileptic drugs.

Promising Areas Still in Early Stages

Here the research is younger, study samples are smaller, and conclusions need to be taken with more caution:

• Anxiety: some recent clinical studies suggest that full-spectrum CBD may be effective and well tolerated, with a better safety profile than traditional medications like benzodiazepines — but larger studies are needed to confirm this at scale
• Neurodegenerative diseases (such as Alzheimer’s and Parkinson’s): preclinical research and some retrospective analyses suggest a potential role in symptom management, but this remains an evolving field rather than an established therapy
• Fibromyalgia: observational studies on patients report perceived improvements in quality of life, but large-scale randomized trials are still lacking
• Inflammatory skin conditions, such as psoriasis: research is exploring CBD’s immunomodulatory effects, with interesting but not yet conclusive preliminary results
• Glaucoma: cannabinoids do reduce intraocular pressure, but the effect is short-lived and would require frequent dosing, making it impractical as a therapy compared to already-available alternatives

Areas That Remain Largely Anecdotal

For some conditions, such as bipolar disorder or schizophrenia, the available evidence remains mostly anecdotal or based on very small studies. In the case of schizophrenia in particular, the relationship between cannabis and psychosis is the subject of a complex and, in some ways, contradictory scientific debate: while CBD is being studied for a possible anti-inflammatory effect on the central nervous system, high-THC cannabis use is instead associated in the literature with an increased risk of psychosis in predisposed individuals. It’s a good example of how “cannabis” isn’t a single, monolithic thing — the ratio between different cannabinoids radically changes the risk-benefit profile.

A Point Often Overlooked: Side Effects

Serious research doesn’t just measure benefits — it measures risks too. Severe adverse effects are relatively rare in clinical studies, but symptoms like drowsiness, dizziness, nausea, dry mouth, and euphoria are common. This is why the scientific literature agrees on one point: therapy should always be managed by an experienced physician, who can assess drug interactions, the patient’s medical history, and individual risk, including the risk of dependence in certain patient populations.

Why Research Is Still Limited

It’s worth remembering something often left out of the conversation: cannabis research has for decades been hindered by its status as an internationally controlled substance, which has historically made it difficult to conduct large-scale studies as easily as with other drugs. This partly explains why, for many conditions, we still have only partial data despite an “informal” use of the plant going back thousands of years. In recent years, with the partial liberalization of research in several countries, the number of randomized clinical trials has grown significantly, and dedicated research centers are producing increasingly solid data.

In Summary

Medical cannabis is neither a miracle cure nor a myth without scientific basis: it’s a class of substances with a highly uneven evidence profile depending on the condition in question. For neuropathic pain, spasticity in multiple sclerosis, and drug-resistant epilepsy, the evidence is relatively strong; for many other conditions, research is promising but still young. In every case, the decision about therapeutic use rests with a physician, who can assess each patient’s specific clinical situation — this article, like the rest of this blog, is for informational purposes only.

---

Note: the content on this blog is for informational and educational purposes only. It does not replace the advice of a qualified doctor or legal professional, and should not be interpreted as personalized therapeutic guidance.